Neuroprotective strategies for NMDAR-mediated excitotoxicity in Huntington’s Disease

Abstract

BACKGROUND: Huntington’s Disease (HD) is an autosomal dominant neurodegenerative disease causing severe neurodegeneration of the striatum as well as marked cognitive and motor disabilities. Excitotoxicity, caused by overstimulation of NMDA receptors (NMDARs) has been shown to have a key role in the neuropathogenesis of HD, suggesting that targeting NMDAR-dependent signaling may be an effective clinical approach for HD. However, broad NMDAR antagonists are generally poor therapeutics in clinical practice. It has been suggested that GluN2A-containing, synaptically located NMDARs activate cell survival signaling pathways, while GluN2B-containing, primarily extrasynaptic NMDARs trigger cell death signaling. A better approach to development of effective therapeutics for HD may be to target, specifically, the cell-death specific pathways associated with extrasynaptic GluN2B NMDAR activation, while maintaining or potentiating the cell-survival activity of GluN2A-NMDARs.

OBJECTIVE: This review outlines the role of NMDAR-mediated excitotoxicity in HD and overviews current efforts to develop better therapeutics for HD where NMDAR excitotoxicity is the target.

METHODS: A systematic review process was conducted using the PubMed search engine focusing on research conducted in the past 5-10 years. 235 articles were consulted for the review, with key search terms including “Huntington’s Disease,” “excitotoxicity,” “NMDAR” and “therapeutics.”

RESULTS: A wide range of NMDAR excitotoxicity-based targets for HD were identified and reviewed, including targeting NMDARs directly by blocking GluN2B, extrasynaptic NMDARs and/or potentiating GluN2A, synaptic NMDARs, targeting glutamate release or uptake, or targeting specific downstream cell-death signaling of NMDARs.

CONCLUSION: The current review identifies NMDAR-mediated excitotoxicity as a key player in HD pathogenesis and points to various excitotoxicity-focused targets as potential future preventative therapeutics for HD.

Key words： Huntington’s Disease; NMDA receptor; excitotoxicity; cell death; therapeutics

Compliance with ethical guidelines

Kimberly Girling and Yu Tian Wang declared that they have no conflict of interest. All institutional and national guidelines for the care and use of laboratory animals were followed. This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

References

1 Aamodt S M, Constantine-Paton M (1999). The role of neural activity in synaptic development and its implications for adult brain function. Adv Neurol, 79: 133–144

PMID

2 Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd J W, Wang Y T, Salter M W, Tymianski M (2002). Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science, 298(5594): 846–850

PMID

3 Abiltrub M, Shattock M ( 2013). Cardiac dysautonomia in Huntington’s disease. J Huntington Dis, 2(3): 251–261

4 Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, Mizuno N (1994). Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol, 347(1): 150–160

PMID

5 Albin R L, Young A B, Penney J B, Handelin B, Balfour R, Anderson K D, Markel D S, Tourtellotte W W, Reiner A (1990). Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington’s disease. N Engl J Med, 322(18): 1293–1298

PMID

6 Arai A, Vanderklish P, Kessler M, Lee K, Lynch G (1991). A brief period of hypoxia causes proteolysis of cytoskeletal proteins in hippocampal slices. Brain Res, 555(2): 276–280

PMID

7 Arlinghaus L, Mehdi S, Lee K S (1991). Improved posthypoxic recovery with a membrane-permeable calpain inhibitor. Eur J Pharmacol, 209(1-2): 123–125

PMID

8 Balázs R, Hack N, Jørgensen O S (1988). Stimulation of the receptor has a trophic effect on differentiating cerebellar granule cells. Neurosci Lett, 87(1–2): 80–86

PMID

9 Balázs R, Hack N,Jørgensen O S ( 1990). Interactive effects involving different classes of excitatory amino acid receptors and the survival of cerebellar granule cells in culture. Int J Dev Neurosci,8(4): 347–359

10 Balázs R, Hack N, Jørgensen O S, Cotman C W (1989). N-methyl-D-aspartate promotes the survival of cerebellar granule cells: pharmacological characterization. Neurosci Lett, 101(3): 241–246

PMID

11 Balázs R, Jørgensen O S, Hack N (1988). N-methyl-D-aspartate promotes the survival of cerebellar granule cells in culture. Neuroscience, 27(2): 437–451

PMID

12 Bano D, Young K W, Guerin C J, Lefeuvre R, Rothwell N J, Naldini L, Rizzuto R, Carafoli E, Nicotera P (2005). Cleavage of the plasma membrane Na⁺/Ca²⁺ exchanger in excitotoxicity. Cell, 120(2): 275–285

PMID

13 Beal M F (1998). Excitotoxicity and nitric oxide in Parkinson’s disease pathogenesis. Ann Neurol, 44(3 Suppl 1): S110–S114

PMID

14 Beal M F, Kowall N W, Ellison D W, Mazurek M F, Swartz K J, Martin J B (1986). Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature, 321(6066): 168–171

PMID

15 Beighton P, Hayden M R (1981). Huntington’s chorea. S Afr Med J, 59(8): 250

PMID

16 Benveniste M, Mayer M L (1991). Kinetic analysis of antagonist action at N-methyl-D-aspartic acid receptors. Two binding sites each for glutamate and glycine. Biophys J, 59(3): 560–573

PMID

17 Berliocchi L, Bano D, Nicotera P (2005). Ca²⁺ signals and death programmes in neurons. Philos Trans R Soc Lond B Biol Sci, 360(1464): 2255–2258

PMID

18 Bliss T V P, Collingridge G L (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 361(6407): 31–39

PMID

19 Brenman J E, Chao D S, Gee S H, McGee A W, Craven S E, Santillano D R, Wu Z, Huang F, Xia H, Peters M F, Froehner S C, Bredt D S (1996). Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell, 84(5): 757–767

PMID

20 Brenneman D E, Forsythe I D, Nicol T, Nelson P G (1990a). N-methyl-D-aspartate receptors influence neuronal survival in developing spinal cord cultures. Brain Res Dev Brain Res, 51(1): 63–68

PMID

21 Brenneman D E, Yu C, Nelson P G (1990b). Multi-determinate regulation of neuronal survival: neuropeptides, excitatory amino acids and bioelectric activity. Int J Dev Neurosci, 8(4): 371–378

23 Burde R M, Schainker B, Kayes J (1971). Acute effect of oral and subcutaneous administration of monosodium glutamate on the arcuate nucleus of the hypothalamus in mice and rats. Nature, 233(5314): 58–60

PMID

24 Burns L H, Pakzaban P, Deacon T W, Brownell A L, Tatter S B, Jenkins B G, Isacson O (1995). Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience, 64(4): 1007–1017

PMID

22 Carroll J, Southwell A L, Graham R K, Lerch J P, Ehrnhoefer D E, Cao L P, Zhang W N, Deng Y, Bissada N, Henkelman R M, Hayden M R (2011). Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Moler Neurodegener, 6(1): 59

PMID

25 Cepeda C, Hurst R S, Calvert C R, Hern�ndez-Echeagaray E, Nguyen O K, Jocoy E, Christian L J, Ariano M A, Levine M S (2003). Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington’s disease. J Neurosci, 23(3): 961–969

PMID

26 Cepeda C, Itri J N, Flores-Hernández J, Hurst R S, Calvert C R, Levine M S (2001). Differential sensitivity of medium- and large-sized striatal neurons to NMDA but not kainate receptor activation in the rat. Eur J Neurosci, 14(10): 1577–1589

PMID

27 Chapman D E, Keefe K A, Wilcox K S (2003). Evidence for functionally distinct synaptic NMDA receptors in ventromedial versus dorsolateral striatum. J Neurophysiol, 89(1): 69–80

PMID

28 Chen M, Lu T J, Chen X J, Zhou Y, Chen Q, Feng X Y, Xu L, Duan W H, Xiong Z Q (2008). Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke, 39(11): 3042–3048

PMID

29 Chen M, Ona V O, Li M, Ferrante R J, Fink K B, Zhu S, Bian J, Guo L, Farrell L A, Hersch S M, Hobbs W, Vonsattel J P, Cha J H, Friedlander R M (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med, 6(7): 797–801

PMID

30 Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden M R, Raymond L A (1999). Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem, 72(5): 1890–1898

PMID

31 Choi D W (1995). Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci, 18(2): 58–60

PMID

32 Choi D W, Koh J Y, Peters S (1988). Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci, 8(1): 185–196

PMID

33 Clements J D, Westbrook G L (1991). Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron, 7(4): 605–613

PMID

46 Cottrell J R, Dubé G R, Egles C, Liu G (2000). Distribution, density, and clustering of functional glutamate receptors before and after synaptogenesis in hippocampal neurons. J Neurophysiol, 84(3): 1573–1587

PMID

34 Cowan C M, Fan M M, Fan J, Shehadeh J, Zhang L Y, Graham R K, Hayden M R, Raymond L A (2008). Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J Neurosci, 28(48): 12725–12735

PMID

35 Coyle J T, Schwarcz R (1976). Lesion of striatal neurones with kainic acid provides a model for Huntington’s chorea. Nature, 263(5574): 244–246

PMID

36 Craven S E, El-Husseini A E, Bredt D S (1999). Synaptic targeting of the postsynaptic density protein PSD-95 mediated by lipid and protein motifs. Neuron, 22(3): 497–509

PMID

37 Cross A J, Slater P, Reynolds G P (1986). Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington’s disease. Neurosci Lett, 67(2): 198–202

PMID

38 Cull-Candy S, Brickley S, Farrant M (2001). NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol, 11(3): 327–335

PMID

39 Cull-Candy S G, Leszkiewicz D N (2004). Role of distinct NMDA receptor subtypes at central synapses. Sci STKE, 2004(255): re16

PMID

40 Dau A, Gladding C M, Sepers M D, Raymond L A (2014). Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice. Neurobiol Dis, 62: 533–542

PMID

41 DeRidder M N, Simon M J, Siman R, Auberson Y P, Raghupathi R, Meaney D F (2006). Traumatic mechanical injury to the hippocampus in vitro causes regional caspase-3 and calpain activation that is influenced by NMDA receptor subunit composition. Neurobiol Dis, 22(1): 165–176

PMID

42 Didier M, Roux P, Piechaczyk M, Verrier B, Bockaert J, Pin J P (1989). Cerebellar granule cell survival and maturation induced by K+ and NMDA correlate with c-fos proto-oncogene expression. Neurosci Lett, 107(1-3): 55–62

PMID

43 DiFiglia M (1990). Excitotoxic injury of the neostriatum: a model for Huntington’s disease. Trends Neurosci, 13(7): 286–289

PMID

44 Dingledine R, Borges K, Bowie D, Traynelis S F (1999). The glutamate receptor ion channels. Pharmacol Rev, 51(1): 7–61

PMID

45 Dragunow M, Faull R L, Lawlor P, Beilharz E J, Singleton K, Walker E B, Mee E (1995). In situ evidence for DNA fragmentation in Huntington’s disease striatum and Alzheimer’s disease temporal lobes. Neuroreport, 6(7): 1053–1057

PMID

47 Ehrlich M E (2012). Huntington’s disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics, 9(2): 270–284

PMID

48 El-Husseini A E, Schnell E, Chetkovich D M, Nicoll R A, Bredt D S (2000). PSD-95 involvement in maturation of excitatory synapses. Science, 290(5495): 1364–1368

PMID

49 Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N, Guillermier M, Brouillet E, Hantraye P, Déglon N, Ferrante R J, Bonvento G (2010). In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington’s disease subjects. Hum Mol Genet, 19(15): 3053–3067

PMID

50 Fan J, Cowan C M, Zhang L Y, Hayden M R, Raymond L A (2009). Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington’s disease. J Neurosci, 29(35): 10928–10938

PMID

51 Fan M M Y, Fernandes H B, Zhang L Y, Hayden M R, Raymond L A (2007). Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington’s disease. J Neurosci, 27(14): 3768–3779

PMID

52 Fan M M Y, Raymond L A (2007). N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington’s disease. Prog Neurobiol, 81(5-6): 272–293

PMID

53 Fan X, Jin W Y, Lu J, Wang J, Wang Y T (2014). Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci, 17(3): 471–480

PMID

55 Ferrante R J, Kowall N W, Beal M F, Martin J B, Bird E D, Richardson E P Jr (1987). Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington’s disease. J Neuropathol Exp Neurol, 46(1): 12–27

PMID

56 Ferrante R J, Kowall N W, Cipolloni P B, Storey E, Beal M F (1993). Excitotoxin lesions in primates as a model for Huntington’s disease: histopathologic and neurochemical characterization. Exp Neurol, 119(1): 46–71

PMID

57 Fischer G, Mutel V, Trube G, Malherbe P, Kew J N, Mohacsi E, Heitz M P, Kemp J A (1997). Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther, 283(3): 1285–1292

PMID

58 Flint A C, Maisch U S, Weishaupt J H, Kriegstein A R, Monyer H (1997). NR2A subunit expression shortens NMDA receptor synaptic currents in developing neocortex. J Neurosci, 17(7): 2469–2476

PMID

59 Foster K A, McLaughlin N, Edbauer D, Phillips M, Bolton A, Constantine-Paton M, Sheng M (2010). Distinct roles of NR2A and NR2B cytoplasmic tails in long-term potentiation. J Neurosci, 30(7): 2676–2685

PMID

60 Franklin J L, Johnson E M Jr (1992). Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium. Trends Neurosci, 15(12): 501–508

PMID

61 Freedman J K, Potts A M (1962). Repression of glutaminase I in the rat retina by administration of sodium-L-glutamate. Invest Ophthalmol, 1: 118–121

PMID

62 Friedman L K (2006). Calcium: a role for neuroprotection and sustained adaptation. Mol Interv, 6(6): 315–329

PMID

63 Gafni J, Ellerby L M (2002). Calpain activation in Huntington’s disease. J Neurosci, 22(12): 4842–4849

PMID

64 Gallagher M J, Huang H, Pritchett D B, Lynch D R (1996). Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem, 271(16): 9603–9611

PMID

65 Gascón S, Sobrado M, Roda J M, Rodríguez-Peña A, Díaz-Guerra M (2008). Excitotoxicity and focal cerebral ischemia induce truncation of the NR2A and NR2B subunits of the NMDA receptor and cleavage of the scaffolding protein PSD-95. Mol Psychiatry, 13(1): 99–114

PMID

54 Gladding C M, Fan J, Zhang L Y, Wang L, Xu J, Li E H, Lombroso P J, Raymond L A (2014). Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model. J Neurochem, 130(1): 145–159

PMID

66 Gladding C M, Raymond L A (2011). Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. Mol Cell Neurosci, 48(4): 308–320

PMID

67 Gladding C M, Sepers M D, Xu J, Zhang L Y, Milnerwood A J, Lombroso P J, Raymond L A (2012). Calpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington’s disease mouse model. Hum Mol Genet, 21(17): 3739–3752

PMID

68 Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J, Gaudilliere B, MacKenzie E T, Rousseau J, Scatton B, (1988). Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther, 247(3): 1211–1221

PMID

69 Gouix E, Léveillé F, Nicole O, Melon C, Had-Aissouni L, Buisson A (2009). Reverse glial glutamate uptake triggers neuronal cell death through extrasynaptic NMDA receptor activation. Mol Cell Neurosci, 40(4): 463–473

PMID

95 Graham D, Darles J, Langer S (1992). The neuroprotective properties of ifenprodil, a novel NMDA receptor antagonist, in neuronal cell culture toxicity studies. Eur J Pharmacol, 226(4): 373–376

PMID

70 Graham R K, Deng Y, Carroll J, Vaid K, Cowan C, Pouladi M A, Metzler M, Bissada N, Wang L, Faull R L, Gray M, Yang X W, Raymond L A, Hayden M R (2010). Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J Neurosci, 30(45): 15019–15029

PMID

71 Graham R K, Deng Y, Slow E J, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, Warby S C, Doty C N, Roy S, Wellington C L, Leavitt B R, Raymond L A, Nicholson D W, Hayden M R (2006a). Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell, 125(6): 1179–1191

PMID

72 Graham R K, Ehrnhoefer D E, Hayden M R (2011). Caspase-6 and neurodegeneration. Trends Neurosci, 34(12): 646–656

PMID

73 Graham R K, Pouladi M A, Joshi P, Lu G, Deng Y, Wu N P, Figueroa B E, Metzler M, Andr� V M, Slow E J, Raymond L, Friedlander R, Levine M S, Leavitt B R, Hayden M R (2009). Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci, 29(7): 2193–2204

PMID

74 Graham R K, Slow E J, Deng Y, Bissada N, Lu G, Pearson J, Shehadeh J, Leavitt B R, Raymond L A, Hayden M R (2006b). Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol Dis, 21(2): 444–455

PMID

75 Graveland G A, Williams R S, DiFiglia M (1985). Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s disease. Science, 227(4688): 770–773

PMID

76 Groc L, Heine M, Cousins S L, Stephenson F A, Lounis B, Cognet L, Choquet D (2006). NMDA receptor surface mobility depends on NR2A-2B subunits. Proc Natl Acad Sci U S A, 103(49): 18769–18774

PMID

237 Grossberg G T, Thomas S J (2009). Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging, 4: 367–377

77 Guidetti P, Bates G P, Graham R K, Hayden M R, Leavitt B R, MacDonald M E, Slow E J, Wheeler V C, Woodman B, Schwarcz R (2006). Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis, 23(1): 190–197

PMID

78 Guidetti P, Luthi-Carter R E, Augood S J, Schwarcz R (2004). Neostriatal and cortical quinolinate levels are increased in early grade Huntington’s disease. Neurobiol Dis, 17(3): 455–461

PMID

79 Guttmann R P, Baker D L, Seifert K M, Cohen A S, Coulter D A, Lynch D R (2001). Specific proteolysis of the NR2 subunit at multiple sites by calpain. J Neurochem, 78(5): 1083–1093

PMID

80 Guttmann R P, Sokol S, Baker D L, Simpkins K L, Dong Y, Lynch D R (2002). Proteolysis of the N-methyl-d-aspartate receptor by calpain in situ. J Pharmacol Exp Ther, 302(3): 1023–1030

PMID

81 Hansson O, Guatteo E, Mercuri N B, Bernardi G, Li X J, Castilho R F, Brundin P (2001). Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci, 14(9): 1492–1504

PMID

82 Hantraye P, Riche D, Maziere M, Isacson O (1990). A primate model of Huntington’s disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol, 108(2): 91–104

PMID

83 Hardingham G E, Bading H (2003). The Yin and Yang of NMDA receptor signalling. Trends Neurosci, 26(2): 81–89

PMID

84 Hardingham G E, Bading H (2010). Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci, 11(10): 682–696

PMID

85 Hardingham G E, Fukunaga Y, Bading H (2002). Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci, 5(5): 405–414

PMID

86 Harjes P, Wanker E E (2003). The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci, 28(8): 425–433

PMID

87 Harris A Z, Pettit D L (2007). Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices. J Physiol, 584(Pt 2): 509–519

PMID

88 Hassel B, Tessler S, Faull R L, Emson P C (2008). Glutamate uptake is reduced in prefrontal cortex in Huntington’s disease. Neurochem Res, 33(2): 232–237

PMID

89 Hayashi T, Thomas G M, Huganir R L (2009). Dual palmitoylation of NR2 subunits regulates NMDA receptor trafficking. Neuron, 64(2): 213–226

PMID

90 Heinsen H, Rüb U, Gangnus D, Jungkunz G, Bauer M, Ulmar G, Bethke B, Schüler M, Böcker F, Eisenmenger W, Götz M, Strik M (1996). Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington’s disease. Acta Neuropathol, 91(2): 161–168

PMID

91 Hermel E, Gafni J, Propp S S, Leavitt B R, Wellington C L, Young J E, Hackam A S, Logvinova A V, Peel A L, Chen S F, Hook V, Singaraja R, Krajewski S, Goldsmith P C, Ellerby H M, Hayden M R, Bredesen D E, Ellerby L M (2004). Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington’s disease. Cell Death Differ, 11(4): 424–438

PMID

92 Hodges A, Strand A D, Aragaki A K, Kuhn A, Sengstag T, Hughes G, Elliston L A, Hartog C, Goldstein D R, Thu D, Hollingsworth Z R, Collin F, Synek B, Holmans P A, Young A B, Wexler N S, Delorenzi M, Kooperberg C, Augood S J, Faull R L, Olson J M, Jones L, Luthi-Carter R (2006). Regional and cellular gene expression changes in human Huntington’s disease brain. Hum Mol Genet, 15(6): 965– 977

PMID

93 Hodgson J G, Agopyan N, Gutekunst C A, Leavitt B R, LePiane F, Singaraja R, Smith D J, Bissada N, McCutcheon K, Nasir J, Jamot L, Li X J, Stevens M E, Rosemond E, Roder J C, Phillips A G, Rubin E M, Hersch S M, Hayden M R (1999). A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron, 23(1): 181–192

PMID

94 Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O’Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012). Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med, 366(10): 893–903

PMID

96 Huang K, Kang M H, Askew C, Kang R, Sanders S S, Wan J, Davis N G, Hayden M R (2010). Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiol Dis, 40(1): 207–215

PMID

97 Huang K, Yanai A, Kang R, Arstikaitis P, Singaraja R R, Metzler M, Mullard A, Haigh B, Gauthier-Campbell C, Gutekunst C A, Hayden M R, El-Husseini A (2004). Huntingtin-interacting protein HIP14 is a palmitoyl transferase involved in palmitoylation and trafficking of multiple neuronal proteins. Neuron, 44(6): 977–986

PMID

98 Hynd M R, Scott H L, Dodd P R (2004). Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int, 45(5): 583–595

PMID

99 Ikonomidou C, Turski L (2002). Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol, 1(6): 383–386

PMID

100 Ishii T, Moriyoshi K, Sugihara H, Sakurada K, Kadotani H, Yokoi M, Akazawa C, Shigemoto R, Mizuno N, Masu M, (1993). Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J Biol Chem, 268(4): 2836–2843

PMID

101 Izumi Y, Tokuda K, Zorumski C F (2008). Long-term potentiation inhibition by low-level N-methyl-D-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase. Hippocampus, 18(3): 258–265

PMID

102 Jarabek B R (2003). Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington’s mouse model. Brain, 127(3): 505–516

103 Johnson J W, Ascher P (1987). Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature, 325(6104): 529–531

PMID

104 Johnston M V (2005). Excitotoxicity in perinatal brain injury. Brain Pathol, 15(3): 234–240

PMID

105 Kaltenbach L S, Romero E, Becklin R R, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, Cha G H, Ukani L, Chepanoske C L, Zhen Y, Sahasrabudhe S, Olson J, Kurschner C, Ellerby L M, Peltier J M, Botas J, Hughes R E (2007). Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet, 3(5): e82

PMID

106 Kandel E R, Schwartz J H, Jessell T M (1995). Essentials of Neural Science and Behavior. McGraw Hill Professional

107 Kassubek J, Bernhard Landwehrmeyer G, Ecker D, Juengling F D, Muche R, Schuller S, Weindl A, Peinemann A (2004). Global cerebral atrophy in early stages of Huntington’s disease: quantitative MRI study. Neuroreport, 15(2): 363–365

PMID

108 Katagiri H, Tanaka K, Manabe T (2001). Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction. Eur J Neurosci, 14(3): 547–553

PMID

109 Katsura K, Ekholm A, Siesjö B K (1992). Coupling among changes in energy metabolism, acid-base homeostasis, and ion fluxes in ischemia. Can J Physiol Pharmacol, 70(Suppl): S170–S175

PMID

110 Kaufman A M, Milnerwood A J, Sepers M D, Coquinco A, She K, Wang L, Lee H, Craig A M, Cynader M, Raymond L A (2012). Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons. J Neurosci, 32(12): 3992–4003

PMID

111 Kew J N, Trube G, Kemp J A (1996). A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol, 497(Pt 3): 761–772

PMID

112 Kim M, Velier J, Chase K, Laforet G, Kalchman M A, Hayden M R, Won L, Heller A, Aronin N, Difiglia M (1999). Forskolin and dopamine D1 receptor activation increase huntingtin’s association with endosomes in immortalized neuronal cells of striatal origin. Neuroscience, 89(4): 1159–1167

PMID

113 Klapstein G J, Fisher R S, Zanjani H, Cepeda C, Jokel E S, Chesselet M F, Levine M S (2001). Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington’s disease transgenic mice. J Neurophysiol, 86(6): 2667–2677

PMID

114 Koike T, Martin D P, Johnson E M Jr (1989). Role of Ca²⁺ channels in the ability of membrane depolarization to prevent neuronal death induced by trophic-factor deprivation: evidence that levels of internal Ca²⁺ determine nerve growth factor dependence of sympathetic ganglion cells. Proc Natl Acad Sci U S A, 86(16): 6421–6425

PMID

115 Kornau H C, Schenker L T, Kennedy M B, Seeburg P H (1995). Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science, 269(5231): 1737–1740

PMID

116 Koutsilieri E, Riederer P (2007). Excitotoxicity and new antiglutamatergic strategies in Parkinson’s disease and Alzheimer’s disease. Parkinsonism Relat Disord, 13(Suppl 3): S329–S331

PMID

117 Kremer B, Clark C M, Almqvist E W, Raymond L A, Graf P, Jacova C, Mezei M, Hardy M A, Snow B, Martin W, Hayden M R (1999). Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology, 53(5): 1000–1011

PMID

118 Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, Masaki H, Kumanishi T, Arakawa M, Mishina M (1992). Molecular diversity of the NMDA receptor channel. Nature, 358(6381): 36–41

PMID

120 Lai T W, Wang Y T (2010). Fashioning drugs for stroke. Nat Med, 16(12): 1376–1378

PMID

121 Lai T W, Zhang S, Wang Y T (2014). Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol, 115: 157–188

PMID

122 Lan J Y, Skeberdis V A, Jover T, Grooms S Y, Lin Y, Araneda R C, Zheng X, Bennett M V, Zukin R S (2001). Protein kinase C modulates NMDA receptor trafficking and gating. Nat Neurosci, 4(4): 382–390

PMID

123 Lee K S, Frank S, Vanderklish P, Arai A, Lynch G (1991). Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc Natl Acad Sci U S A, 88(16): 7233–7237

PMID

124 Lee M S, Kwon Y T, Li M, Peng J, Friedlander R M, Tsai L H (2000). Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature, 405(6784): 360–364

PMID

125 Lester R A J, Clements J D, Westbrook G L, Jahr C E (1990). Channel kinetics determine the time course of NMDA receptor-mediated synaptic currents. Nature, 346(6284): 565–567

PMID

126 Levine M S, Klapstein G J, Koppel A, Gruen E, Cepeda C, Vargas M E, Jokel E S, Carpenter E M, Zanjani H, Hurst R S, Efstratiadis A, Zeitlin S, Chesselet M F (1999). Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res, 58(4):515–532

127 Levine M S, Klapstein G J, Koppel A, Gruen E, Cepeda C, Vargas M E, Jokel E S, Carpenter E M, Zanjani H, Hurst R S, Efstratiadis A, Zeitlin S, Chesselet M F (1999). Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington’s disease. J Neurosci Res, 58(4): 515–532

PMID

128 Li J H, Wang Y H, Wolfe B B, Krueger K E, Corsi L, Stocca G, Vicini S (1998). Developmental changes in localization of NMDA receptor subunits in primary cultures of cortical neurons. Eur J Neurosci, 10(5): 1704–1715

PMID

119 Li L, Murphy T H, Hayden M R, Raymond L A (2004). Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J Neurophysiol, 92(5): 2738–2746

PMID

239 Li X, Standley C, Sapp E, Valencia A, Qin Z H, Kegel K B, Yoder J, Comer-Tierney L A, Esteves M, Chase K, Alexander J, Masso N, Sobin L, Bellve K, Tuft R, Lifshitz L, Fogarty K, Aronin N, DiFiglia M (2009). Mutant Huntingtin Impairs Vesicle Formation from Recycling Endosomes by Interfering with Rab11 Activity. Mol Cell Biol, 29(22): 6106–6116

PMID

240 Li S, Jin M, Koeglsperger T, Shepardson N E, Shankar G M, Selkoe D J (2011). Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci, 31(8): 6627–6638

PMID

129 Liévens J C, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, Bates G P (2001). Impaired glutamate uptake in the R6 Huntington’s disease transgenic mice. Neurobiol Dis, 8(5): 807–821

PMID

130 Lim D, Fedrizzi L, Tartari M, Zuccato C, Cattaneo E, Brini M, Carafoli E (2008). Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem, 283(9): 5780–5789

PMID

131 Lin Y, Skeberdis V A, Francesconi A, Bennett M V, Zukin R S (2004). Postsynaptic density protein-95 regulates NMDA channel gating and surface expression. J Neurosci, 24(45): 10138–10148

PMID

132 Lipton S A (2004a). Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx, 1(1): 101–110

133 Lipton S A (2004b). Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders. J Alzheimers Dis, 6(6 Suppl): S61–S74

PMID

134 Liu D D, Yang Q, Li S T (2013). Activation of extrasynaptic NMDA receptors induces LTD in rat hippocampal CA1 neurons. Brain Res Bull, 93: 10–16

PMID

135 Liu L, Wong T P, Pozza M F, Lingenhoehl K, Wang Y, Sheng M, Auberson Y P, Wang Y T (2004). Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science, 304(5673): 1021–1024

PMID

136 Liu Y, Wong T P, Aarts M, Rooyakkers A, Liu L, Lai T W, Wu D C, Lu J, Tymianski M, Craig A M, Wang Y T (2007). NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci, 27(11): 2846–2857

PMID

137 López-Menéndez C, Gascón S, Sobrado M, Vidaurre O G, Higuero A M, Rodríguez-Peña A, Iglesias T, Díaz-Guerra M (2009). Kidins220/ARMS downregulation by excitotoxic activation of NMDARs reveals its involvement in neuronal survival and death pathways. J Cell Sci, 122(Pt 19): 3554–3565

PMID

138 Lu W, Man H, Ju W, Trimble W S, MacDonald J F, Wang Y T (2001). Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron, 29(1): 243–254

PMID

139 Lucas D R, Newhouse J P (1957). The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol, 58(2): 193–201

PMID

140 MacDermott A B, Mayer M L, Westbrook G L, Smith S J, Barker J L (1986). NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature, 321(6069): 519–522

PMID

141 MacDonald M E, , and the The Huntington’s Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell, 72(6): 971–983

PMID

142 Man H Y, Wang Q, Lu W Y, Ju W, Ahmadian G, Liu L, D’Souza S, Wong T P, Taghibiglou C, Lu J, Becker L E, Pei L, Liu F, Wymann M P, MacDonald J F, Wang Y T (2003). Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons. Neuron, 38(4): 611–624

PMID

143 Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies S W, Bates G P (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87(3): 493–506

PMID

144 Marklund N, Bakshi A, Castelbuono D J, Conte V, McIntosh T K (2006). Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr Pharm Des, 12(13): 1645–1680

PMID

145 Martel M A, Ryan T J, Bell K F, Fowler J H, McMahon A, Al-Mubarak B, Komiyama N H, Horsburgh K, Kind P C, Grant S G, Wyllie D J, Hardingham G E (2012). The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron, 74(3): 543–556

PMID

146 Martel M A, Wyllie D J A, Hardingham G E (2009). In developing hippocampal neurons, NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience, 158(1): 334–343

PMID

147 Martin H G S, Wang Y T (2010). Blocking the deadly effects of the NMDA receptor in stroke. Cell, 140(2): 174–176

PMID

148 Matsumoto T, Obrenovitch T P, Parkinson N A, Symon L (1990). Cortical activity, ionic homeostasis, and acidosis during rat brain repetitive ischemia. Stroke, 21(8): 1192–1198

PMID

149 Mattison H A, Hayashi T, Barria A (2012). Palmitoylation at two cysteine clusters on the C-terminus of GluN2A and GluN2B differentially control synaptic targeting of NMDA receptors. PLoS One, 7(11): e49089

PMID

150 Mayer M L, Westbrook G L, Guthrie P B (1984). Voltage-dependent block by Mg²⁺ of NMDA responses in spinal cord neurones. Nature, 309(5965): 261–263

PMID

151 McGeer E G, McGeer P L (1976). Duplication of biochemical changes of Huntington’s chorea by intrastriatal injections of glutamic and kainic acids. Nature, 263(5577): 517–519

154 Miller B R, Dorner J L, Shou M, Sari Y, Barton S J, Sengelaub D R, Kennedy R T, Rebec G V (2008). Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington’s disease phenotype in the R6/2 mouse. Neuroscience, 153(1): 329–337

PMID

155 Milnerwood A J, Cummings D M, Dallérac G M, Brown J Y, Vatsavayai S C, Hirst M C, Rezaie P, Murphy K P (2006). Early development of aberrant synaptic plasticity in a mouse model of Huntington’s disease. Hum Mol Genet, 15(10): 1690–1703

PMID

156 Milnerwood A J, Gladding C M, Pouladi M A, Kaufman A M, Hines R M, Boyd J D, Ko R W, Vasuta O C, Graham R K, Hayden M R, Murphy T H, Raymond L A (2010). Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice. Neuron, 65(2): 178–190

PMID

153 Milnerwood A J, Kaufman A M, Sepers M D, Gladding C M, Zhang L, Wang L, Fan J, Coquinco A, Qiao J Y, Lee H, Wang Y T, Cynader M, Raymond L A (2012). Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice. Neurobiol Dis, 48(1): 40–51

PMID

157 Milnerwood A J, Raymond L A (2007). Corticostriatal synaptic function in mouse models of Huntington’s disease: early effects of huntingtin repeat length and protein load. J Physiol, 585(Pt 3): 817–831

PMID

158 Minnerup J, Sutherland B A, Buchan A M, Kleinschnitz C (2012). Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci, 13(9): 11753–11772

PMID

159 Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg P H (1992). Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science, 256(5060): 1217–1221

PMID

160 Mori H,Mishina M (1996). Molecular diversity and physiological roles of the NMDA-receptor channel. Nihon Yakurigaku Zasshi, 108(1): 1–12

161 Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S (1991). Molecular cloning and characterization of the rat NMDA receptor. Nature, 354(6348): 31–37

PMID

162 Murphy K P, Carter R J, Lione L A, Mangiarini L, Mahal A, Bates G P, Dunnett S B, Morton A J (2000). Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington’s disease mutation. J Neurosci, 20(13): 5115–5123

PMID

163 O’Donnell L A, Agrawal A, Jordan-Sciutto K L, Dichter M A, Lynch D R, Kolson D L (2006). Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes. J Neurosci, 26(3): 981–990

PMID

164 Obrenovitch T P, Urenjak J (1997). Is high extracellular glutamate the key to excitotoxicity in traumatic brain injury? J Neurotrauma, 14(10): 677–698

PMID

165 Okamoto S, Pouladi M A, Talantova M, Yao D, Xia P, Ehrnhoefer D E, Zaidi R, Clemente A, Kaul M, Graham R K, Zhang D, Vincent Chen H S, Tong G, Hayden M R, Lipton S A (2009). Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med, 15(12): 1407–1413

PMID

166 Olney J W, Sharpe L G (1969). Brain lesions in an infant rhesus monkey treated with monsodium glutamate. Science, 166(3903): 386–388

PMID

167 Papadia S, Stevenson P, Hardingham N R, Bading H, Hardingham G E (2005). Nuclear Ca²⁺ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J Neurosci, 25(17): 4279–4287

PMID

168 Papouin T, Ladépêche L, Ruel J, Sacchi S, Labasque M, Hanini M, Groc L, Pollegioni L, Mothet J P, Oliet S H (2012). Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell, 150(3): 633–646

PMID

169 Parsons M P, Raymond L A (2014). Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron, 82(2): 279–293

PMID

170 Parsons M P, Vanni M P, Woodard C L, Kang R, Murphy T H, Raymond L A (2016). Real-time imaging of glutamate clearance reveals normal striatal uptake in Huntington disease mouse models. Nat Commun, 7: 11251

PMID

171 Patrick G N, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai L H (1999). Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature, 402(6762): 615–622

PMID

172 Paul S, Nairn A C, Wang P, Lombroso P J (2003). NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat Neurosci, 6(1): 34–42

PMID

173 Petralia R S, Wang Y X, Hua F, Yi Z, Zhou A, Ge L, Stephenson F A, Wenthold R J (2010). Organization of NMDA receptors at extrasynaptic locations. Neuroscience, 167(1): 68–87

PMID

174 Pop C, Salvesen G S (2009). Human caspases: activation, specificity, and regulation. J Biol Chem, 284(33): 21777–21781

PMID

175 Pouladi M A, Graham R K, Karasinska J M, Xie Y, Santos R D, Petersén A, Hayden M R (2009). Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain, 132(Pt 4): 919–932

PMID

176 Prybylowski K, Chang K, Sans N, Kan L, Vicini S, Wenthold R J (2005). The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron, 47(6): 845–857

PMID

177 Rami A, Krieglstein J (1993). Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res, 609(1-2): 67–70

PMID

178 Rosas H D, Koroshetz W J, Chen Y I, Skeuse C, Vangel M, Cudkowicz M E, Caplan K, Marek K, Seidman L J, Makris N, Jenkins B G, Goldstein J M (2003). Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology, 60(10): 1615–1620

PMID

179 Rosenmund C, Clements J D, Westbrook G L (1993). Nonuniform probability of glutamate release at a hippocampal synapse. Science, 262(5134): 754–757

PMID

180 Saavedra A, Giralt A, Rué L, Xifró X, Xu J, Ortega Z, Lucas J J, Lombroso P J, Alberch J, Pérez-Navarro E (2011). Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington’s disease: a STEP in the resistance to excitotoxicity. J Neurosci, 31(22): 8150–8162

PMID

181 Sanberg P R, Calderon S F, Giordano M, Tew J M, Norman A B (1989). The quinolinic acid model of Huntington’s disease: locomotor abnormalities. Exp Neurol, 105(1): 45–53

PMID

241 Sanberg P R, Lehmann J, Fibiger H C (1978). Impaired learning and memory after kainic acid lesions of the striatum: a behavioral model of Huntington’s disease. Brain Res, 149(2): 549–551

PMID

182 Sánchez I, Xu C J, Juo P, Kakizaka A, Blenis J, Yuan J (1999). Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron, 22(3): 623–633

PMID

242 Sanders S, Hayden M (2015). Aberrant palmitoylation in Huntington disease. BiochmSoc Trans, 43(2): 205–210

PMID

183 Sanz-Clemente A, Nicoll R A,Roche K W (2013). Diversity in NMDA receptor composition: many regulators, many consequences. Neuroscientist, 19(1): 62–75

184 Sattler R, Tymianski M (2000). Molecular mechanisms of calcium-dependent excitotoxicity. J Mol Med (Berl), 78(1): 3–13

PMID

185 Sattler R, Xiong Z, Lu W Y, Hafner M, MacDonald J F, Tymianski M (1999). Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science, 284(5421): 1845–1848

PMID

186 Sawa A, Wiegand G W, Cooper J, Margolis R L, Sharp A H, Lawler J F Jr, Greenamyre J T, Snyder S H, Ross C A (1999). Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med, 5(10): 1194–1198

PMID

187 Schwarcz R, Bennett J P Jr, Coyle J T Jr (1977). Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with Huntington’s Disease. J Neurochem, 28(4): 867–869

PMID

188 Shehadeh J, Fernandes H B, Zeron Mullins M M, Graham R K, Leavitt B R, Hayden M R, Raymond L A (2006). Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis, 21(2): 392–403

PMID

189 Sheng M, Cummings J, Roldan L A, Jan Y N, Jan L Y (1994). Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature, 368(6467): 144–147

PMID

190 Shirasaki D I, Greiner E R, Al-Ramahi I, Gray M, Boontheung P, Geschwind D H, Botas J, Coppola G, Horvath S, Loo J A, Yang X W (2012). Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron, 75(1): 41–57

PMID

191 Siman R, Noszek J C (1988). Excitatory amino acids activate calpain I and induce structural protein breakdown in vivo. Neuron, 1(4): 279–287

PMID

192 Singaraja R R, Hadano S, Metzler M, Givan S, Wellington C L, Warby S, Yanai A, Gutekunst C A, Leavitt B R, Yi H, Fichter K, Gan L, McCutcheon K, Chopra V, Michel J, Hersch S M, Ikeda J E, Hayden M R (2002). HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet, 11(23): 2815–2828

PMID

193 Singaraja R R, Huang K, Sanders S S, Milnerwood A J, Hines R, Lerch J P, Franciosi S, Drisdel R C, Vaid K, Young F B, Doty C, Wan J, Bissada N, Henkelman R M, Green W N, Davis N G, Raymond L A, Hayden M R (2011). Altered palmitoylation and neuropathological deficits in mice lacking HIP14. Hum Mol Genet, 20(20): 3899– 3909

PMID

194 Spargo E, Everall I P, Lantos P L (1993). Neuronal loss in the hippocampus in Huntington’s disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry, 56(5): 487–491

PMID

195 Sprengel R, Suchanek B, Amico C, Brusa R, Burnashev N, Rozov A, Hvalby O, Jensen V, Paulsen O, Andersen P, Kim J J, Thompson R F, Sun W, Webster L C, Grant S G, Eilers J, Konnerth A, Li J, McNamara J O, Seeburg P H (1998). Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo. Cell, 92(2): 279–289

PMID

196 Strand A D, Baquet Z C, Aragaki A K, Holmans P, Yang L, Cleren C, Beal M F, Jones L, Kooperberg C, Olson J M, Jones K R (2007). Expression profiling of Huntington’s disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci, 27(43): 11758–11768

PMID

197 Sun Y, Savanenin A, Reddy P H, Liu Y F (2001). Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem, 276(27): 24713–24718

PMID

198 Sun Z, Del Mar N, Meade C, Goldowitz D, Reiner A (2002). Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington’s disease. Neurobiol Dis, 11(3): 369–385

PMID

199 Sutton L M, Sanders S S, Butland S L, Singaraja R R, Franciosi S, Southwell A L, Doty C N, Schmidt M E, Mui K K, Kovalik V, Young F B, Zhang W, Hayden M R (2013). Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease. Hum Mol Genet, 22(3): 452–465

PMID

200 Tabrizi S J, Workman J, Hart P E, Mangiarini L, Mahal A, Bates G, Cooper J M, Schapira A H (2000). Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol, 47(1): 80–86

PMID

201 Tallaksen-Greene S J, Janiszewska A, Benton K, Ruprecht L, Albin R L (2010). Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. Exp Neurol, 225(2): 402–407

PMID

202 Tang T S, Slow E, Lupu V, Stavrovskaya I G, Sugimori M, Llinás R, Kristal B S, Hayden M R, Bezprozvanny I (2005). Disturbed Ca²⁺ signaling and apoptosis of medium spiny neurons in Huntington’s disease. Proc Natl Acad Sci U S A, 102(7): 2602–2607

PMID

203 Terasaki Y, Sasaki T, Yagita Y, Okazaki S, Sugiyama Y, Oyama N, Omura-Matsuoka E, Sakoda S, Kitagawa K (2010). Activation of NR2A receptors induces ischemic tolerance through CREB signaling. J Cereb Blood Flow Metab, 30(8): 1441–1449

204 The Huntington’s Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell, 72(6): 971–983

PMID

205 Thomas C G, Miller A J, Westbrook G L (2006). Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J Neurophysiol, 95(3): 1727–1734

PMID

243 Tobin A J (2004). G. Bates, P. Harper, L. Jones (eds). Huntington’S disease, Third edition. Human Genet, 114(3): 320–321

PMID

206 Tovar K R, McGinley M J, Westbrook G L (2013). Triheteromeric NMDA receptors at hippocampal synapses. J Neurosci, 33(21): 9150–9160

PMID

207 Tovar K R, Westbrook G L (1999). The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci, 19(10): 4180–4188

PMID

208 Tu W, Xu X, Peng L, Zhong X, Zhang W, Soundarapandian M M, Balel C, Wang M, Jia N, Zhang W, Lew F, Chan S L, Chen Y, Lu Y (2010). DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell, 140(2): 222–234

PMID

245 Tymianski M (2004). Stroke in 2013: Disappointments and advances in acute stroke intervention. Nat Rev Neurol, 10(2): 66–68

PMID

209 Uribe V, Wong B K, Graham R K, Cusack C L, Skotte N H, Pouladi M A, Xie Y, Feinberg K, Ou Y, Ouyang Y, Deng Y, Franciosi S, Bissada N, Spreeuw A, Zhang W, Ehrnhoefer D E, Vaid K, Miller F D, Deshmukh M, Howland D, Hayden M R (2012). Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Hum Mol Genet, 21(9): 1954–1967

PMID

210 Usdin M T, Shelbourne P F, Myers R M, Madison D V (1999). Impaired synaptic plasticity in mice carrying the Huntington’s disease mutation. Hum Mol Genet, 8(5): 839–846

PMID

212 Van Raamsdonk J M, Pearson J, Slow E J, Hossain S M, Leavitt B R, Hayden M R (2005). Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington’s disease. J Neurosci, 25(16): 4169–4180

PMID

213 Vonsattel J P, Myers R H, Stevens T J, Ferrante R J, Bird E D, Richardson E P Jr (1985). Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol, 44(6): 559–577

PMID

214 Wang C X, Shuaib A (2005). NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. Curr Drug Targets CNS Neurol Disord, 4(2): 143–151

PMID

215 Wang Y, Briz V, Chishti A, Bi X, Baudry M (2013). Distinct roles for m-calpain and m-calpain in synaptic NMDAR-mediated neuroprotection and extrasynaptic NMDAR-mediated neurodegeneration. J Neurosci, 33(48): 18880–18892

PMID

216 Warby S C, Doty C N, Graham R K, Carroll J B, Yang Y Z, Singaraja R R, Overall C M, Hayden M R (2008). Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum Mol Genet, 17(15): 2390–2404

PMID

217 Watkins J C, Evans R H (1981). Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol, 21(1): 165–204

PMID

211 Wellington C, Ellerby L M, Gutekunst C A, Rogers D, Warby S, Graham R K, Loubser O, van Raamsdonk J, Singaraja R, Yang Y Z, Gafni J, Bredesen D, Hersch S M, Leavitt B R, Roy S, Nicholson D W, Hayden M R (2002). Caspase cleavage of mutant Huntingtin precedes Neurodegeneration in Huntington’s disease. J Neurosci, 22(18): 7862–7872

PMID

218 Wellington C L, Ellerby L M, Hackam A S, Margolis R L, Trifiro M A, Singaraja R, McCutcheon K, Salvesen G S, Propp S S, Bromm M, Rowland K J, Zhang T, Rasper D, Roy S, Thornberry N, Pinsky L, Kakizuka A, Ross C A, Nicholson D W, Bredesen D E, Hayden M R (1998). Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem, 273(15): 9158–9167

PMID

219 Wellington C L, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, Nicholson D W, Bredesen D E, Hayden M R (2000). Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem, 275(26): 19831–19838

PMID

220 Williams K (1993). Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol, 44(4): 851–859

PMID

221 Wong B K Y, Ehrnhoefer D E, Graham R K, Martin D D, Ladha S, Uribe V, Stanek L M, Franciosi S, Qiu X, Deng Y, Kovalik V, Zhang W, Pouladi M A, Shihabuddin L S, Hayden M R (2015). Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiol Dis, 76: 24–36

PMID

222 Wroge C M, Hogins J, Eisenman L, Mennerick S (2012). Synaptic NMDA receptors mediate hypoxic excitotoxic death. J Neurosci, 32(19): 6732–6742

PMID

223 Xia P, Chen H S, Zhang D, Lipton S A (2010). Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci, 30(33): 11246–11250

PMID

224 Xu J, Kurup P, Zhang Y, Goebel-Goody S M, Wu P H, Hawasli A H, Baum M L, Bibb J A, Lombroso P J (2009). Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci, 29(29): 9330–9343

PMID

225 Yamazaki M, Mori H, Araki K, Mori K J, Mishina M (1992). Cloning, expression and modulation of a mouse NMDA receptor subunit. FEBS Lett, 300(1): 39–45

PMID

226 Yan G M, Ni B, Weller M, Wood K A, Paul S M (1994). Depolarization or glutamate receptor activation blocks apoptotic cell death of cultured cerebellar granule neurons. Brain Res, 656(1): 43–51

PMID

227 Young A B, Greenamyre J T, Hollingsworth Z, Albin R, D’Amato C, Shoulson I, Penney J B (1988). NMDA receptor losses in putamen from patients with Huntington’s disease. Science, 241(4868): 981–983

PMID

246 Young F B, Butland S L, Sanders S S, Sutton L M, Hayden M R (2012). Putting proteins in their place: Palmitoylation in Huntington disease and other neuropsychiatric diseases. Prog Neurobiol, 97(2): 220– 238

PMID

228 Yuan H, Myers S J, Wells G, Nicholson K L, Swanger S A, Lyuboslavsky P, Tahirovic Y A, Menaldino D S, Ganesh T, Wilson L J, Liotta D C, Snyder J P, Traynelis S F (2015). Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects. Neuron, 85(6): 1305– 1318

PMID

229 Zeron M M, Hansson O, Chen N, Wellington C L, Leavitt B R, Brundin P, Hayden M R, Raymond L A (2002). Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron, 33(6): 849–860

PMID

247 Zeron M M, Fernandes H B, Krebs C, Shehadeh J, Wellington C L, Leavitt B R, Baimbridge K G, Hayden M R, Raymond L A (2004). Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington’s disease. Mol Cell Neurosci, 25(3): 469–479

PMID

230 Zhang Q G, Wu D N, Han D, Zhang G Y (2007). Critical role of PTEN in the coupling between PI3K/Akt and JNK1/2 signaling in ischemic brain injury. FEBS Lett, 581(3): 495–505

PMID

231 Zhang S, Taghibiglou C, Girling K, Dong Z, Lin S Z, Lee W, Shyu W C, Wang Y T (2013). Critical role of increased PTEN nuclear translocation in excitotoxic and ischemic neuronal injuries. J Neurosci, 33(18): 7997–8008

PMID

232 Zhang S J, Steijaert M N, Lau D, Sch�tz G, Delucinge-Vivier C, Descombes P, Bading H (2007). Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron, 53(4): 549–562

PMID

233 Zhou L, Li F, Xu H B, Luo C X, Wu H Y, Zhu M M, Lu W, Ji X, Zhou Q G, Zhu D Y (2010). Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat Med, 16(12): 1439–1443

PMID

234 Zhou M, Baudry M (2006). Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J Neurosci, 26(11): 2956–2963

PMID

235 Zhou X, Ding Q, Chen Z, Yun H, Wang H (2013). Involvement of the GluN2A and GluN2B subunits in synaptic and extrasynaptic N-methyl-D-aspartate receptor function and neuronal excitotoxicity. J Biol Chem, 288(33): 24151–24159

PMID

236 Zuccato C, Valenza M, Cattaneo E (2010). Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev, 90(3): 905–981